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The importance of interactions between allergen and IgE in allergen-mediated activation of T lymphocytes from
patients with atopic dermatitis (AD) is unclear. A role for this interaction is implied by past evidence for IgE-
facilitated presentation of allergen to T cells, but this phenomenon has only been demonstrated in speciﬁc in vitro
systems biased to maximize the effect. It is therefore not known whether the process is relevant in patients. We now
show that the responses to allergen of unmodiﬁed peripheral blood mononuclear cells (PBMC) from individual AD
patients are signiﬁcantly greater in the presence of fresh, unheated, IgE-containing autologous serum than the
same serum heated under IgE-denaturing conditions or speciﬁcally depleted of IgE by immunoprecipitation. In six
independent experiments, 59%–67% of the maximal in vitro PBMC response to allergen was found to be dependent
upon the presence of IgE in autologous serum used at 5% ﬁnal concentration. These data provide the ﬁrst evidence
that sufﬁcient amounts of allergen-speciﬁc IgE and allergen-reactive T cells occur concomitantly in the blood of
individual AD patients to allow IgE-enhanced T cell responses to allergen. We conclude that IgE-enhanced T cell
responses are pathophysiologically relevant and a therapeutic target in AD.
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The role of IgE-mediated cellular responses to common
environmental allergens in the pathogenesis of atopic
dermatitis (AD) has been controversial. Some have sug-
gested that the raised serum IgE levels in patients with AD
often appear incidental to the disease process (Holden and
Parish, 1998). Although disputed by some (Bos, 2002),
others have also introduced the concept of ‘‘intrinsic’’ AD as
defining patients, including adults, with clinically typical skin
disease but without evidence for raised serum levels of total
or allergen-specific IgE (Walker et al, 1993). We have,
however, found ‘‘intrinsic’’ AD to be rare in the British East
Midlands region, at least in adults, in that total serum IgE
and IgE specific for Dermatophagoides pteronyssinus (Der
p) allergens were raised in all of 20 randomly selected adults
with AD attending our clinics (Shah et al, 2002). A further
finding in these studies was that in vitro peripheral blood
mononuclear cell (PBMC) responses to Der p allergen were
substantially and consistently lower when assays were
carried out with heat-treated allogeneic AB serum rather
than fresh, unheated autologous serum (Shah et al, 2002).
This allows the speculation that Der p-specific IgE in
autologous serum may play a key role in the generation of
in vitro PBMC responses to this allergen in individual
patients.
Indeed, evidence suggests that the focusing of allergens
by IgE bound to Fce receptors on antigen-presenting cells
(APC), may enhance the efficacy of allergen processing and
presentation to T cells by up to 1000-fold (van der Heijden
et al, 1993; Maurer et al, 1995). The phenomenon of IgE-
facilitated allergen presentation (FAP) that may critically
lower the threshold of atopic individuals to mount allergen-
specific T cell responses, however, has only been demon-
strated in in vitro systems that were wholly or partially
biased to maximize the likelihood of demonstrating this
process. Thus, IgE-FAP via high-affinity IgE receptors
(FceRI) on monocytes has been demonstrated in a system
that used monocyte-enriched PBMC as APC, allergen-
specific responder T cell clones, hapten-specific chimeric
IgE, and purified, haptenized allergen (Maurer et al, 1995). A
similar approach was used to demonstrate IgE-FAP via
FceRI on peripheral blood dendritic cells (Maurer et al,
1996). IgE-FAP via the low-affinity IgE receptor (FceRII/
CD23) on B cells has also been demonstrated by using
selected Epstein–Barr virus-transformed B cell lines, teta-
nus toxoid-specific Tcell clones, haptenized tetanus toxoid,
and hapten-specific chimeric IgE (Pirron et al, 1990). In a
system that employed more pathophysiologically relevant
forms of allergen and IgE, Epstein–Barr virus-transformed
B cell lines were used to demonstrate CD23-dependent
enhancement of the responses of autologous Der p allergen
II-specific T cell clones to unpurified protein extract of Der p
by atopic sera containing Der p II-specific IgE (van der
Heijden et al, 1993; van der Heijden et al, 1995). We are,
however, unaware of any reports that confirm IgE-FAP in
Abbreviations: AD, atopic dermatitis; cpm, counts per minute;
Der p, Dermatophagoides pteronyssinus; FAP, facilitated allergen
presentation; FceRI, high-affinity IgE receptor; FceRII/CD23, low-
affinity IgE receptor; PBMC, peripheral blood mononuclear cells;
SI, stimulation index
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in vitro systems that have not used enriched APC popula-
tions and allergen-specific T cell clones or lines. Therefore,
the pathophysiologic relevance of IgE-FAP and the con-
tribution of allergen-specific IgE to allergen-induced T cell
responses in individual patients, as well as the potential of
this process as a therapeutic target, all remain unclear.
Our previous finding that PBMC responses to Der p were
greater in assays containing unheated autologous as
opposed to heated allogeneic AB serum (Shah et al, 2002)
suggests but does not confirm that sufficient numbers of
allergen-reactive T cells and adequate amounts of cor-
responding allergen-specific IgE may be concomitantly
available in individual atopic subjects to allow a significant
level of IgE-FAP. In view of this and the nature of the
previous experiments demonstrating IgE-FAP, which do not
clarify the pathogenic relevance of this process in individual
patients, we have asked whether the enhanced responses
of PBMC to Der p extract in the presence of unheated
autologous as opposed to allogeneic AB serum are due to
the presence of IgE. To avoid the introduction of bias, we
have used unpurified Der p extract in cultures containing
autologous serum and density gradient-purified but other-
wise unmodified PBMC from volunteers with AD, with the
aim of obtaining an approximate quantification of the
contribution of allergen-specific IgE to T cell responses to
allergen in individual AD patients.
Results
PBMC responses to Der p extract in the presence of
unmodiﬁed and heated serum Nine adults with AD,
whose PBMC showed concentration-related responses to
Der p extract, donated venous blood samples for these
studies. The PBMC of these donors were consistently and
significantly more responsive to Der p extract in cultures
containing fresh, unmodified autologous serum than in
cultures containing autologous serum heated at 561C for
60 min (Fig 1, Table I). These findings supported but did not
prove a role for IgE in enhancing responses of atopic PBMC
to Der p.
In contrast to the effects of unheated autologous atopic
serum, unheated serum from non-atopic controls did not
enhance PBMC responses to Der p above that seen with
heated autologous atopic serum (Fig 2). Repeated assays
with PBMC from different non-atopic controls failed to show
responses to a full range of concentrations of Der p extract
in the presence of 10% autologous serum (n¼ 9, data not
shown). Furthermore, responses of non-atopic PBMC
remained at background levels (o600 cpm (counts per
minute)) when 10% unheated atopic serum containing Der
p-specific IgE was used instead of the autologous serum
(n¼3, data not shown).
Effects of serum IgE depletion Immunoreactive IgE levels
in serum during depletion by immunoprecipitation are
shown in Fig 3A. Serum from an AD patient with a high
total IgE level was used in the experiment shown. Three
Table I. Maximum SI values obtained from proliferation assays
with atopic PBMC, a range of concentrations of Der p extract
and medium supplemented with 10% fresh autologous serum
(either unmodiﬁed or heated at 561C for 60 min)
Patienta Unmodiﬁed serum Heated serum
AD4 23.3b 1.4
AD8 29.2 3.8
AD9 19.1 7.1
AD15 20.7 7.2
AD16 12.8 7.6
AD17 44.3 9.4
AD18 70.7 20.2
AD19 43.0 18.0
AD20 9.6 2.8
Mean  SD 30.3  19.3c 8.6  6.5c
aResults of assays with PBMC and autologous serum from nine
different AD patients are shown.
bMaximum SI represents the highest response to Der p extract in cpm
divided by cpm in the absence of allergen. In six cases, maximum SI
values are obtained from data shown in Fig 1.
cp¼0.002, paired t test.
SI, stimulation index; PBMC, peripheral blood mononuclear cells; Der
p, Dermatophagoides pteronyssinus; AD, atopic dermatitis; cpm, counts
per minute.
Figure 1
Proliferative responses of peripheral blood mononuclear cells
(PBMC) from atopic dermatitis (AD) patients to Dermatophagoides
pteronyssinus (Der p) allergen in the presence of unmodified or
heated autologous serum. Responses in the presence of medium
containing 10% fresh, unmodified autologous serum (shaded symbols)
or 10% fresh, autologous serum that had been heated at 561C for 60
min (open symbols) are shown. The results of independent experiments
with PBMC and autologous sera from six different patients are given.
Results are expressed as counts per minute (cpm), each point showing
the mean of triplicate assays, with SD values. Where SD values are not
shown, they are less than the diameter of the symbol.
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rounds of depletion by the described Dynabead method
were necessary and sufficient to remove ELISA-detectable
IgE from this atopic serum sample. Because of the pos-
sibility of complement activation during immunoprecipi-
tation of IgE in unheated serum, and the unpredictable
effects of complement products on Tcell function (Dempsey
et al, 1996; Kemper et al, 2003), ELISA measurements of
the complement activation product, iC3b, were made
during incubation of atopic serum with anti-IgE- and control
antibody-coated Dynabeads. As shown in Fig 3B, immu-
noreactive iC3b levels were detectable in all samples
tested, including serum kept on ice in the absence of
antibody-Dynabead conjugates, indicating a degree of
spontaneous complement activation as has been reported
previously in normal human serum (Manderson et al, 2001).
Immunoreactive iC3b levels in untreated serum fell within
the range (5–78 mg per mL) found following the analysis
of 100 normal serum samples (information from Quidel
Corporation, San Diego, California). Increased levels of iC3b
were detectable in serum samples incubated with antibody–
Figure 2
Effects of non-atopic serum on responses of peripheral blood
mononuclear cells (PBMC) from an atopic dermatitis (AD) patient
to Dermatophagoides pteronyssinus (Der p) allergen. The serum
used was either autologous or from a healthy, non-atopic donor, and
was either unmodified or heated at 561C for 60 min. Symbols
representing the different sera used are indicated in the figure. Results
are expressed as counts per minute (cpm) and are the mean of
triplicate assays. SD values were less than 30% of the means. Similar
results were obtained in a second, independent experiment.
Figure 3
IgE depletion and complement activation in atopic serum, and
dependence of peripheral blood mononuclear cell (PBMC) re-
sponses on autologous serum concentration. (A) Immunoreactive
IgE levels in atopic serum before (unshaded column) and after depletion
by the Dynabead immunoprecipitation method. IgE levels following
each of three rounds of treatment with Dynabeads coupled to control
antibody (shaded columns) or anti-IgE antibody (hatched columns), are
shown. IgE levels were determined by ELISA after dilution of serum 2–
100-fold with the sample diluent provided, and the mean results of
duplicate assays are shown. The limit of detection of the ELISA was
about 2 IU per mL. Results are representative of three independent
experiments. (B) Immunoreactive iC3b levels in untreated atopic sera
(unshaded columns) or sera treated with Dynabeads (Db) coupled to
isotype control monoclonal antibody (shaded columns) or anti-IgE
monoclonal antibody (hatched columns). Serum samples were freshly
prepared on ice and antibody-coupled Dynabeads added at time zero.
The samples were then kept on ice for 15 and 60 min prior to ELISA,
which was carried out as described under Materials and Methods. Data
represent the means of duplicate ELISA measurements, and are from
four independent experiments. (C) Responses of PBMC from an AD
patient to Der p allergen in medium supplemented with four different
concentrations of fresh, unmodified autologous serum (1%, 2.5%, 5%,
and 10%). The responses of PBMC to Der p allergen in the presence of
10% autologous serum heated at 561C for 60 min are shown for
comparison. Each point shows the mean of triplicate assays. SD values
are less than 30% of the means. Results are representative of four
independent experiments.
1088 COOPER ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Dynabead conjugates, but there was little or no difference in
the levels in sera treated with anti-IgE or control antibody for
15 or 60 min (Fig 3B). Complement activation could
therefore not explain the results obtained in subsequent
experiments, in which the responses of atopic PBMC to Der
p in the presence of IgE-depleted or control autologous
serum were determined. Prior to the IgE-depletion experi-
ments, the concentration of fresh, unmodified autologous
serum required to support maximum responses of the
atopic PBMC to Der p was determined. Here, 10% and 5%
(vol/vol) final concentrations of autologous serum supported
similar responses of the PBMC to Der p, whereas 2.5%
and 1% serum gave lower responses (Fig 3C). For cost
effectiveness, IgE-depleted or control sera at 5% final
concentration were used in cultures with autologous PBMC
from six different AD patients. Responses to Der p extract
were consistently and significantly lower in cultures contain-
ing IgE-depleted versus control serum (Fig 4, Table II).
Discussion
Der p extract was chosen for use in these studies because
of our previous work showing correlation between in vitro
PBMC responses to this allergen in the presence of 10%
fresh, autologous serum and the ability to induce dermatitis
by repeated topical challenge of the elbow flexures of
patients with AD (Shah et al, 2002). This previous work
showed that the major population of cells amongst PBMC
from AD patients that undergo proliferation in response to
Der p extract are CD4þ T cells (Shah et al, 2002). In this
work, we have also found that the PBMC of non-atopic
donors do not respond to Der p extract in the presence of
10% serum, either autologous or from AD patients, a find-
ing that also indicates that the Der p extract was not
contaminated by endotoxin or other non-specific mitogens.
On this basis, we have concluded that the Der p extract is a
clinically relevant allergen preparation with which to explore
the pathophysiologic relevance of IgE in the responses of
PBMC from AD patients. The assays were not biased to
maximize IgE-enhanced T cell responses, unlike previous
work with enriched APC populations, allergen-specific Tcell
clones and chimeric IgE molecules (Pirron et al, 1990; van
der Heijden et al, 1993; Maurer et al, 1995, 1996; van der
Heijden et al, 1995; van Neerven et al, 1999).
Our finding that the responses of PBMC from AD patients
to Der p extract were strikingly greater in the presence of
unmodified autologous serum than autologous serum
containing IgE irreversibly denatured by heating, provided
preliminary evidence for pathophysiologically relevant IgE-
enhanced responses, but this was not conclusive as the
heating method is likely to denature heat-labile molecules
other than IgE. Subsequently, the use of sera specifically
depleted of IgE by immunoprecipitation was found con-
sistently to be associated with significantly lower responses
of autologous atopic PBMC to Der p allergen than control
autologous sera. Before concluding that the diminished
responses to Der p allergen in assays with IgE-depleted
serum were specifically due to lack of IgE, it was necessary
to exclude effects of complement activation by IgE immune
complexes during the depletion process. The earlier work of
others indicates that fragments of the third component of
Table II. Maximum SI values obtained from proliferation as-
says with atopic PBMC, a range of concentrations of Der p
extract and medium supplemented with 5% fresh autologous
serum (either IgE-depleted or control)
Patient
Control
serum
IgE-depleted
serum
Percentage
reduction
AD4 28.1a 11.5 59.1
AD8 13.4 5.6 58.2
AD9 53.3 24.8 53.5
AD15 12.0 5.4 55.0
AD17 4.7 1.7 63.8
AD20 12.0 4.0 66.7
Mean  SD 20.6  17.8b 8.8  8.5b 59.4
aMaximum SI represents the highest response to Der p extract in cpm
divided by cpm in the absence of allergen. Values are derived from the six
assays shown in Fig 4.
bp¼ 0.027, paired t test.
SI, stimulation index; PBMC, peripheral blood mononuclear cells; Der
p, Dermatophagoides pteronyssinus; AD, atopic dermatitis; cpm, counts
per minute.
Figure 4
Proliferative responses of peripheral blood mononuclear cells
(PBMC) from atopic dermatitis (AD) patients to Dermatophagoides
pteronyssinus (Der p) allergen in the presence of IgE-depleted
serum. Medium was supplemented either with 5% control autologous
serum (shaded symbols) or 5% autologous serum depleted of IgE by
immunoprecipitation (open symbols). Results are expressed as counts
per minute (cpm) and are from independent experiments with PBMC
and sera from six different patients. Each point shows the mean of
triplicate assays with SD values.
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complement inhibit mitogen- and antigen-induced human
lymphocyte blastogenesis (Ballas et al, 1983) and that the
C3 fragment C3b suppresses monocyte-dependent T cell
proliferation (Da¨ubener et al, 1987). More recent research
has also indicated a direct or indirect inhibitory effect of
complement activation on T cell responses (Kemper et al,
2003; Sohn et al, 2003). In these experiments, however,
there was no evidence for greater complement activation in
IgE-containing serum incubated with anti-IgE-coated Dy-
nabeads than in serum cultured with beads coated with
control antibody. Consequently, the reduced atopic PBMC
responses found in cultures containing autologous serum
depleted of IgE by antibody treatment cannot be explained
by the production of complement products that inhibit Tcells.
Attempts were made to confirm the IgE-dependence of
atopic PBMC responses to Der p extract by using Fce
receptor blocking antibodies in assays containing fresh
autologous serum. Isotype control murine monoclonal
antibody, however, caused consistent inhibitory effects that
were reproduced with a second isotype control antibody
(data not shown). This non-specific inhibitory phenomenon
was not investigated further, but led to abandonment of the
use of blocking antibodies in the present work.
The use of IgE-depleted serum in the described PBMC
proliferation assays shows that sufficient amounts of Der p-
specific IgE and Der p-reactive T cells occur concomitantly
in the blood of individual adult AD patients to allow
enhancement of T cell responses to allergen by IgE-
dependent mechanisms, probably via the process of IgE-
FAP. As shown in Table II, 59%–67% of the maximal in vitro
PBMC response to allergen was found to be dependent
upon the presence of IgE in autologous serum used at 5%
final concentration. We therefore conclude that IgE-depen-
dent enhancement of T cell responses to allergen is a
pathophysiologically relevant process in AD. The findings
also justify further exploration of agents that abrogate IgE-
FAP as a therapeutic measure in AD. Such agents are
attractive as they would not cause indiscriminate immuno-
suppression.
Materials and Methods
Blood donors Following ethical committee approval, repeated
heparinized venous blood samples were obtained from nine
informed, consenting adults with AD. The patients (six males and
three females aged 21–61 y), who satisfied standard diagnostic
criteria for AD (Hanifin and Rajka, 1980) and had not received
systemic immunosuppressant drugs or ultraviolet phototherapy for
at least 3 mo, were recruited from the dermatology clinic of the
Leicester Royal Infirmary. As is the case in the large majority of
adults with AD attending this clinic (Shah et al, 2002), the patients
recruited for the present study had raised serum levels of total IgE
(691–40,960 U per mL, UniCAP 100 assay, Pharmacia Diagnostics,
Milton Keynes, UK) and Der p-specific IgE (40–3064 U per mL,
ImmunoCAP assay, Pharmacia Diagnostics). All had previously
shown in vitro PBMC responses to Der p extract. Venous blood
samples were also obtained from healthy adults donors with no
personal or family history of atopic disorders.
Preparation of PBMC and sera Heparinized venous blood was
diluted 1:1 in Earle’s balanced salts solution (Life Technologies,
Paisley, UK) and PBMC recovered by standard density-gradient
centrifugation over Lymphoprep (Life Technologies). Interface cells
were pelleted, washed in Earle’s balanced salts solution and
resuspended in RPMI-1640 medium containing up to 10% fresh
autologous serum. Sera were prepared by allowing blood to clot in
glass tubes, aspiration and centrifugation to remove residual cells.
In some experiments, the culture medium contained serum that
was either unmodified or heated at 561C for 60 min, conditions that
irreversibly denature IgE amongst other molecules (Geha et al,
1985; Ishizaka et al, 1986), but not IgG (Shakib et al, 1992). Atopic
sera specifically depleted of IgE were prepared by immunopreci-
pitation using protein G Dynabeads (Dynal, Bromborough, UK).
Briefly, 100–500 mL aliquots of Dynabeads from the supplied
suspension were washed in 0.1 M sodium phosphate buffer (pH
5.0) then reacted with an excess (100–500 mg) of solid-phase-
absorbed polyclonal rabbit anti-human IgE (product code A0094,
DakoCytomation, Ely, UK) or 100–500 mg control solid-phase-
absorbed antibody from non-immunized rabbit serum (product
code X0936, DakoCytomation) for 40 min at room temperature.
The coated beads were washed twice in ice-cold 0.1 M sodium
phosphate buffer (pH 5.0) and once in RPMI-1640 that was then
removed and the isolated beads mixed with 100–500 mL fresh
atopic serum at 41C for 60 min with continual rotation. Serum was
recovered and subjected to two further rounds of treatment with
fresh aliquots of antibody-coated Dynabeads. In preliminary IgE
depletions, the serum level of total IgE was measured by ELISA
(Autogen Bioclear, Calne, UK) after each round of treatment with
antibody-coated Dynabeads. Evidence for complement activation
during IgE depletion was also determined by incubating atopic
serum with antibody-coated Dynabeads for 15 and 60 min at 41C.
After these time periods, sera were diluted 10-fold with ice-cold
0.1 M EDTA prior to a further 20-fold dilution with sample diluent
and assay for the complement activation product iC3b by Quidel
ELISA (Technoclone, Dorking, UK) according to the manufacturer’s
instructions.
PBMC proliferation assays Culture medium consisted of RPMI-
1640 with penicillin and streptomycin (1% vol/vol of stock solutions
containing 10 kU per mL and 10 mg per mL of the respec-
tive antibiotics). PBMC (5  105 per mL) were cultured in this
medium, to which had been added up to 10% autologous serum
(unmodified, heated or IgE-depleted) and Der p extract, for 5 d in
microtiter plate wells. During the last 6 h each well was pulsed with
1 mCi tritiated thymidine, cells were harvested and incorporated
radioactivity determined and expressed as cpm or alternatively as
stimulation indices (SI, cpm in the presence of allergen divided by
background cpm). In certain experiments, PBMC from AD patients
were mixed with serum from non-atopic controls, and PBMC from
non-atopic controls incubated with atopic serum. Der p extract
used in the PBMC proliferation assays was prepared by dialysis
of Soluprick SQ 10 Hep skin prick test solution (Alk-Abello´,
Hungerford, UK) against RPMI-1640 containing penicillin and
streptomycin. The protein concentration was determined by the
Lowry method (Lowry et al, 1951) and aliquots stored at 801C.
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